Presented once every three years since 1977, the award recognizes an individual who has made outstanding contributions to the study of the prostate gland and its associated diseases.
An internationally recognized authority in prostate disease, Dr. McConnell was cited by the American Urological Association (AUA) for his innovative research studies of prostate enlargement, a condition known as benign prostatic hyperplasia (BPH), and for his leadership in developing a multidisciplinary program at University of Texas (UT)Southwestern that brought together basic and clinical research, innovative patient care and health-care policy in prostate disease.
Dr. McConnell’s research findings include the discovery that combining the drugs alpha-blocking doxazosin and finasteride is more effective for treating BPH than using either drug separately. “I look at the award as recognition of the entire UT Southwestern team,” said Dr. McConnell. “Years ago Dr. Claus Roehrborn [UT Southwestern chairman of urology] and I envisioned a team of gifted physicians and scientists who could fundamentally change the way BPH is managed around the world. I share this honour with them.”
Dr. McConnell served as chairman of urology at UT Southwestern from 1993 to 2001 and is currently responsible for the overall management of UT Southwestern University Hospital, outpatient clinics and physician practice in an integrated health system. Dr. McConnell is the author of more than 100 publications in the field of basic and clinical prostate disease research. In 2004 he was elected to the Institute of Medicine, a component of the prestigious National Academy of Sciences.
MEDICA.de; Source: UT Southwestern Medical Center